Interferon treatment for chronic hepatitis B or C infection: Costs and effectiveness

Acta Gastro-Enterologica Belgica

Volumn 61, Issue 2, 1998, Pages 238-242

  Wong, John B ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Chronic hepatitis; Cirrhosis; Cost benefit; Hepatitis B; Hepatitis C; Interferon

Indexed keywords

INTERFERON;

CHRONIC HEPATITIS; COMPUTER SIMULATION; CONFERENCE PAPER; COST BENEFIT ANALYSIS; HEALTH CARE MANAGEMENT; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; SOCIAL STATUS; TREATMENT PLANNING; VIREMIA;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIFE EXPECTANCY; MALE; MARKOV CHAINS; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 0031866984     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. DRUMMOND M.F., O'BRIEN B.J., STODDART G L , TORRANCE G W. Methods for the Economic Evaluation of Health Care Programmes. Second ed Oxford. Oxford University Press, 1997.
2. GOLD M.R, SIEGEL J.E., RUSSELL L.B., WEINSTEIN M.C. Costeffectiveness in health and medicine New York, Oxford University Press, 1996
3. WEINSTEIN M.C., STASON W.B. Foundations of cost-effectiveness analysis for health and medical practices N Engl. J Med., 1977, 296 716-21
4. EISENBERG J-M. Clinical economics A guide to the economic analysis of clinical practices JAMA, 1989, 262 2879-86.
5. DETSKY A S , NAGLIE I G. A clinician's guide to cost-effectiveness analysis. Ann Intern. Med., 1990, 113 : 147-54
6. BENNETT W G., PAUKER S G., DAVIS G L , WONG J B. Modeling therapeutic benefit in the midst of uncertainty : therapy for hepatitis C. Dig Dis. Sci, 1996, 41 (12 suppl.). 56S-62S.
7. WONG J.B., MOSKOWITZ A.J , PAUKER S.G. Clinical decision analysis using microcomputers. A case of coexistent hepatocellular carcinoma and abdominal aortic aneurysm. West. J. Med., 1986, 145 (6) : 805-15
8. WONG J.B., KOFF R.S., TINE F., PAUKER S.G. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann. Intern. Med., 1995, 122 (9) : 664-75.
9. BENNETT W G., INOUE Y., BECK J.R., WONG J.B., PAUKER S.G., DAVIS G.L Estimates of the cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C. Ann Intern Med., 1997, 127 (10) : 855-65
10. SONNENBERG F.A., BECK J.R. Markov models in medical decision making : a practical guide. Med Decis. Making, 1993, 13 : 322-338
11. BECK J R., PAUKER S.G. The Markov Process in medical prognosis Med. Decis. Making., 1983, 3 : 419-58
12. SHINDO M., ARAI K., SOKAWA Y., OKUNO T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy. Ann. Intern Med, 1995, 122 (8) : 586-91.
13. TSEVAT J., WEINSTEIN M.C, WILLIAMS L.W., TOSTESON A.N., GOLDMAN L. Expected gains in life expectancy from various coronary heart disease risk factor modifications Circulation. 1991, 83 : 1194-201.
14. KIM W R , POTERUCHA J.J., HERMANS J.E. et al. Cost-effectiveness of 6 and 12 months of interferon-α therapy for chronic hepatitis C. Ann. Intern. Med., 1997, 127 (10) : 866-74.
15. GOLDMAN L., GORDON D.J., RIFKIND B.M. et al. Cost and health implications of cholesterol lowering. Circulation, 1992, 85 : 1960-8.
16. BONIS P A., IOANNIDIS J.P.A., CAPPELLERI J C., KAPLAN M M., LAU J. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C : A meta-analysis of diagnostic test characteristics. Hepatology, 1997, 26 (10) : 1035-44
17. KOFF R Interferon-α for chronic hapatitis C : reducing the uncertainties. Ann. Intern Med., 1997, 127 (10) : 918-20.
18. LOUIS-JACQUES O , OLSON A.D. Cost-benefit analysis of interferon therapy in children with chronic active hepatitis B. Journal of Pediatric Gastroenterology & Nutrition, 1997, 24 (1) : 25-32.
19. GARCIA DE ANCOS J L, ROBERTS J.A , DUSHEIKO G.M. An economic evaluation of the costs of alpha-interferon treatment of chronic active hepatitis due to hepatitis B or C virus. J. Hepatol., 1990, 11 (suppl. 1) : S11-8.
20. SHIELL A., BRIGGS A., FARRELL G.C. The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis. Med. J. Aust., 1994, 160 : 268-72.
21. DUSHIEKO G.M., ROBERTS J.A. Treatment of chronic type B and C hepatitis with interferon alfa an economic appraisal. Hepatology, 1995, 22 : 1863-73.